HK inno.N announced on the 25th that it has signed an exclusive license contract for Denosumab biosimilar, a treatment for preventing osteoporosis and cancer-related skeletal complications in Mabxience, Spain. HK inno.N will receive an exclusive supply of two Denosumab biosimilars from Mabxience to apply for and sell domestic licenses. Denosumab is an antibody treatment that targets the RANKL protein, which is key to the survival and function of osteoblasts and exhibits a strong bone absorption inhibitory effect. The original is Prolia60mg, a cancer osteoporosis treatment, and Xgeva 120mg, which is used to prevent skeletal complications in patients with metastatic cancer and treat osteoporosis. Both products were rele